MTOR and breast carcinoma: In the present work we assessed the influence of doxorubicin treatment on PTEN and Akt-mTOR-S6K signaling, and the interaction between doxorubicin and the Akt inhibitor A-443654 in ER positive and negative human breast cancer cell lines in vitro and in vivo.